[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -0.84% 5.90 76,618 14:58:08
Bid Price Offer Price High Price Low Price Open Price
5.80 6.00 5.95 5.90 5.95
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.19 -3.21 -1.82 16
Last Trade Time Trade Type Trade Size Trade Price Currency
14:58:08 O 30 5.80 GBX

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Investors    Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date Time Title Posts
21/10/202108:03Evgen Pharma: Undoubted Transformational Upside Potential2,181
02/9/202111:17Timboisab–āllend17
02/9/202110:06Evgen Guild thread149
12/7/202118:47EVG - A Good Short?87
07/4/202121:06Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer7,271

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:58:085.80301.74O
13:58:085.80170.99O
13:58:085.8019011.02O
13:58:035.9010,000590.00O
13:57:425.8110,000581.00O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

DateSubject
27/10/2021
09:20
Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 5.95p.
Evgen Pharma Plc has a 4 week average price of 5.60p and a 12 week average price of 4.95p.
The 1 year high share price is 12.88p while the 1 year low share price is currently 4.35p.
There are currently 274,888,117 shares in issue and the average daily traded volume is 162,337 shares. The market capitalisation of Evgen Pharma Plc is £16,218,398.90.
20/9/2021
07:08
moneymunch: RNS Number : 1988M Evgen Pharma PLC 20 September 2021 Evgen Pharma plc ("Evgen" or the "Company") Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in glioblastoma cells (GBM) generated by Dr Euphemia Leung and Prof Bruce Baguley of the University of Auckland, New Zealand in the pre-print journal BioRxIV (Leung, Wright and Baguley, 2021 https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1). The in vitro data show effectiveness of the Company's lead asset SFX-01 in glioblastoma cells and 3D spheroids from several patients in New Zealand, together with the more commonly used commercially available cell lines. 3D spheroids are aggregations of tumour cells that more closely reflect the structure of tumours in patients. In these in vitro experiments, SFX-01 demonstrated inhibition of glioblastoma cell growth, confirming work previously announced by the Company in another academic centre. Evgen recently announced the grant of Orphan Drug Designation in the USA for Malignant Glioma, affording the programme additional data protection and other incentives. Dr Huw Jones, CEO of Evgen, commented: "This careful and well-controlled set of experiments by Dr Leung and Prof Baguley confirm work communicated to us by Dr Festuccia of the University of L'Aquila, Abruzzo, Italy and are now available through the rapid publication BioRxIV. We noted the effects observed by the Auckland group in a previous communication and the data are now available for inspection via the journal. They serve to confirm the potential efficacy of SFX-01 in cells that are arguably more disease relevant than those more commonly used.''
06/9/2021
12:01
moneymunch: Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio Once considered “undruggable,” the phosphatase enzyme SHP2 has seen recent interest from a suite of Big Pharmas, including AstraZeneca, Amgen, Novartis and Merck. Now Bristol Myers Squibb is getting in on the action, with a deal to pair its PD-1 superstar Opdivo with BridgeBio’s SHP2 inhibitor for difficult-to-treat cancers. BMS and BridgeBio took the wraps off the non-exclusive, co-funded collaboration early Tuesday morning. The “catalyst,R21; BridgeBio CBO Michael Henderson said, was last year’s virtual JP Morgan conference, where the companies met to discuss early preclinical results they were seeing between SHP2 and immuno-oncology therapies. SHP2 is a phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. What does that mean? Overexpression of SHP2, for instance, has a downstream signaling effect on tumor cell growth. It’s been suggested that SHP2 has an effect on the tumor microenvironment, and sensitivity to immuno-oncology therap     13 July 2021 Evgen Pharma plc ("Evgen" or "the Company") Early data for SFX-01 in leukaemia cell lines Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in in vitro models of certain blood cancers. The data were generated by Dr Eleni Louka and Professor Adam Mead of the MRC Weatherall Institute of Molecular Medicine at Oxford University. The study investigated the effect of SFX-01 on cells from tissue donated by patients with Juvenile Myelomonocytic Leukaemia ("JMML"), through the UK Paediatric MDS/JMML study. These patients carry a specific mutation of the PTPN11 gene. The data demonstrated significant reduction of cell proliferation and increased apoptosis (cell death) of JMML stem cells in the presence of SFX-01, compared to normal controls. The study also showed that SFX-01 significantly impacted cell proliferation and increased cytotoxicity in GDM-1 cells, an Acute Myelomonocytic Leukaemia cell line ("AML"). Whilst this is preliminary data from a small sample size, the Company was encouraged to observe a statistically significant effect in reducing cell proliferation and increasing apoptosis. The PTPN11 gene codes for the SHP2 protein (Src homology-2 domain-containing protein tyrosine phosphatase-2). In January, Evgen announced in-vitro and in-vivo data generated by Professor Philip Eaton, Queen Mary University of London, demonstrating that SFX-01 modifies SHP2. Mutations of the PTPN11 gene are among the commonest molecular defects described in JMML patients, indicating that SFX-01 should be investigated further as a potential disease modifying agent in PTPN11-mutated haematological malignancies. The Company is now assessing the optimal preclinical and clinical strategy for a development programme of SFX-01 in blood cancers such as JMML and AML and will update shareholders when this is completed. Dr Huw Jones, CEO of Evgen Pharma, commented: "The data from Oxford and Queen Mary's shows a very exciting opportunity to extend our oncology pipeline by adding blood cancers to the ongoing metastatic breast cancer and glioblastoma programmes. We are grateful to Professor Eaton, Professor Mead and Dr Louka for their thoughtful and well conducted work on these important cancers."
02/9/2021
11:35
moneymunch: On the US radar!!! ;-) 02 September 2021 Evgen Pharma plc ("Evgen" or the "Company") Glioma Orphan Drug designation for SFX-01 granted by FDA Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces the grant of an Orphan Drug Designation ("OD") by the US Food and Drug Administration ("FDA") for use of SFX-01 to treat malignant glioma. The Company, announced submission of an Orphan Drug application to the FDA on 13 July 2021. OD is usually granted when there are fewer than 200,000 patients with a given disease in the United States and there is a scientific rationale for potential use of the product in that condition. As well as recognising the relative rareness of a disease, OD confers intellectual property cover to an investigational drug in the form of data protection at the time of approval of a new drug application, which is additional to any patent cover in force. Tax credits are also possible on eventual US sales of an approved orphan drug. Dr Huw Jones, CEO of Evgen, commented: "We are delighted that our team and advisors have successfully gained Orphan Drug designation for SFX-01 in the USA in a very short period of time. This is part of a wider strategy to access the US market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering."
17/7/2021
09:09
moneymunch: 14/6/21 Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces new preclinical data which shows SFX-01 may be of benefit to metastatic breast cancer ("mBC") patients who have become resistant to CDK4/6 inhibitors. Since the STEM open-label Phase II trial of SFX-01 in mBC trial concluded, CDK4/6 inhibitors have become standard of care as the first line mBC treatment for the large group of patients who are estrogen receptor positive (ER+ve). These drugs provide an extended period of progression-free survival, but invariably patients' tumours become resistant to them. Options for such patients are limited, especially since drugs used in this setting are poorly tolerated. Accordingly, Evgen's collaborators at the Manchester Breast Centre, the University of Manchester, are conducting further in vitro preclinical work to assess the impact of SFX-01 in CDK4/6 resistance models. An increasing body of in vitro data from there shows that in these models SFX-01 may suppress tumour growth and metastasis in patients who have become resistant to CDK4/6 inhibitors. In particular, SFX-01 reduces the viability and mammosphere colony formation ability of palbociclib-resistant cells in vitro. Palbociclib is the leading CDK4/6 inhibitor. Marketed by Pfizer, it had sales of circa $5bn in 2019. Mammospheres are colonies of primary tumour cells which represent a disease-relevant model to study drug effectiveness. Should these data be reinforced with in vivo work, the Company will pursue a Phase II placebo-controlled study a in second line ER+ve mBC treatment of patients who have failed on CDK4/6 inhibitors. Such a trial could commence in 2022. The Company's previous open-label STEM trial in patients who had not received CDK4/6 inhibitors demonstrated: Dr Huw Jones, CEO of Evgen, commented: "It is exciting that the preliminary data set generated by our colleagues at the Manchester Breast Centre suggests SFX-01 may have a valuable role in the treatment of patients who have developed CDK4/6 resistance patients. We will soon be proceeding with the in vivo work and we are working up the design of the next trial." https://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-Progress-on-metastatic-breast-can/85346839
13/7/2021
17:21
moneymunch: Evgen Pharma PLC 13 July 2021 Evgen Pharma plc ("Evgen" or the "Company") Result of AGM and Business Update Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, is pleased to provide a business update following today's Annual General Meeting, at which all resolutions were duly passed. The AGM voting results will be available on the Company's website later today: https://evgen.com/investors/shareholder-information/ During the last few months we have made significant progress in our glioblastoma ('GBM') development programme, building on exciting initial data from the University L'Aquila which demonstrated tumour shrinkage and significantly extended survival times in in vivo models of GBM. Further work at The University of Auckland and with a Clinical Research Organisation has substantiated and expanded upon important elements of these data, and we are well-advanced in generating a pre-clinical data package that would justify moving into a Phase II clinical trial. We currently project such a trial commencing in the first half of 2022. In parallel with this activity, we have applied for Orphan Drug status for SFX-01 in GBM from the US Food and Drug Administration (FDA) and we are compiling an Investigational New Drug application to be submitted to the FDA later this year. As announced earlier today, we are pleased to report preliminary in vitro data showing the significant reduction of cell proliferation and increased apoptosis (cell death) of Juvenile Myelomonocytic Leukaemia stem cells in the presence of SFX-01, compared to normal controls. The study also showed that SFX-01 significantly impacted cell proliferation and increased cytotoxicity in GDM-1 cells, an Acute Myelomonocytic Leukaemia cell line. The data were generated by Dr Eleni Louka and Professor Adam Mead of the MRC Weatherall Institute of Molecular Medicine at Oxford University. We are investigating options for building on this data with potential scientific partners. Whilst we were disappointed with the outcome of the STAR trial (SFX-01 in Acute Respiratory Distress Syndrome patients) we would emphasise that this was an opportunistic trial funded almost entirely by third parties. Analysis of the unblinded data from the trial will generate substantial bioanalytical insight from the treated patients, which will be valuable to our further development programmes. Last month we were pleased to report that our collaborators at the Manchester Breast Centre, the University of Manchester, are conducting further in vitro preclinical work to assess the impact of SFX--01 in CDK4/6 resistance models. An increasing body of data from there shows that in these models SFX--01 may suppress tumour growth and metastasis in patients who have become resistant to CDK4/6 inhibitors (palbociclib, Ibrance, Pfizer). In particular, SFX--01 reduced the viability and mammosphere colony formation ability of palbociclib--resistant cells in vitro. In summary, the Company is well funded to execute pre-clinical and/or clinical programmes in oncology and looks forward to updating the market on these programmes in due course. An updated presentation on the Company is available on at: hTtps://evgen.com/investors/shareholder-information/ under 'Latest AGM Presentation'.
13/7/2021
07:03
moneymunch: RNS Number : 9887E Evgen Pharma PLC 13 July 2021   Evgen Pharma plc ("Evgen" or "the Company")   Early data for SFX-01 in leukaemia cell lines   Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in in vitro models of certain blood cancers.   The data were generated by Dr Eleni Louka and Professor Adam Mead of the MRC Weatherall Institute of Molecular Medicine at Oxford University. The study investigated the effect of SFX-01 on cells from tissue donated by patients with Juvenile Myelomonocytic Leukaemia ("JMML"), through the UK Paediatric MDS/JMML study. These patients carry a specific mutation of the PTPN11 ;gene. The data demonstrated significant reduction of cell proliferation and increased apoptosis (cell death) of JMML stem cells in the presence of SFX-01, compared to normal controls. The study also showed that SFX-01 significantly impacted cell proliferation and increased cytotoxicity in GDM-1 cells, an Acute Myelomonocytic Leukaemia cell line ("AML").   Whilst this is preliminary data from a small sample size, the Company was encouraged to observe a statistically significant effect in reducing cell proliferation and increasing apoptosis.   The PTPN11 ;gene codes for the SHP2 protein (Src homology-2 domain-containing protein tyrosine phosphatase-2). In January, Evgen announced in-vitro and in-vivo data generated by Professor Philip Eaton, Queen Mary University of London, demonstrating that SFX-01 modifies SHP2. Mutations of the PTPN11 ;gene are among the commonest molecular defects described in JMML patients, indicating that SFX-01 should be investigated further as a potential disease modifying agent in PTPN11-mutated haematological malignancies.   The Company is now assessing the optimal preclinical and clinical strategy for a development programme of SFX-01 in blood cancers such as JMML and AML and will update shareholders when this is completed. Dr Huw Jones, CEO of Evgen Pharma, commented: "The data from Oxford and Queen Mary's shows a very exciting opportunity to extend our oncology pipeline by adding blood cancers to the ongoing metastatic breast cancer and glioblastoma programmes. We are grateful to Professor Eaton, Professor Mead and Dr Louka for their thoughtful and well conducted work on these important cancers."  
09/7/2021
17:46
diamondstar1: Despite some of my negativity with regards to the STAR Trial, I believe that ex-CEO Stephen Franklin’s initiative to get the trial started with Prof. Chalmers was simply BRILLIANT. Why? Because so much free money was available for COVID research, it was simply another opportunity to raise the profile of Evgen. This has allowed Evgen to raise a further round of funding at a higher share price, and attract institutional investors. Without the STAR Trial and interest in COVID - my feeling is that share price would dropped further - and they would have had to raise funding at much lower valuations. So, at least current share price is underpinned by cash in hand circa £10 million. But think about this guys - why have they now failed on 2 occasions in getting a positive trial result ie for SAH and now ARDS? They are not selecting their disease targets properly! Why is US-based Reata Pharmaceuticals - founded in 2002 (with their lead product Bardoloxone - a NRF2 upregulator) - worth $5 billion in market cap? Why is Evgen Pharma - founded in 2007 - with NRF2 activator SFX-01 - only valued at £13 million?
18/6/2021
07:01
moneymunch: RNS Number : 3049C Evgen Pharma PLC 18 June 2021 Evgen Pharma plc ("Evgen" or the "Company") Posting of Annual Report and Notice of AGM Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that its Annual Report and Accounts for the year ended 31 March 2021, the Notice of Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders later today and will be available to download from the Company website shortly. The Company will hold its AGM on Tuesday, 13 July 2021 at 2pm at its offices in Alderley Park. Since laws and the UK Government's guidance regarding the COVID-19 pandemic current on Tuesday 13 July 2021 continue to include the enforcement of social distancing and restrictions on indoor meetings, shareholders will not be permitted to attend the AGM and a closed meeting will be held. Accordingly, the business at the AGM will be curtailed to the formal business section only, with no wider presentations on business performance or question and answer session and any relevant shareholder updates will be made via RNS announcements. Similarly, proxies other than the Chairman will not be able to attend the Meeting in person or cast the shareholder's vote. Shareholders are therefore strongly encouraged to appoint the Chairman of the AGM as their proxy. Details on how to do this are set out on the Form of Proxy being posted to shareholders today. Any shareholder wishing to ask questions regarding the business of the AGM is encouraged to submit their questions to the Board by email to evgen@walbrookpr.com at least seven days in advance of the AGM. The Board will consider all questions and, if appropriate, will provide a written response.
14/6/2021
07:02
moneymunch: RNS Number : 7157B Evgen Pharma PLC 14 June 2021 14 June 2021 Evgen Pharma plc ("Evgen" or the "Company") Progress with Glioma/Glioblastoma programme Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces further progress and an update on clinical trial plans for SFX-01 in glioblastoma ("GBM"). Glioma is the most common form of brain tumour affecting around 5 per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour representing 45% of all cases and has a poor prognosis with median survival of around 14 months. Together with neuroblastoma, GBMs now account for more deaths in the under 40s than any other tumour. Previously the Company reported that these data generated by Dr Claudio Festuccia at University L'Aquila showed that with in vivo pre-clinical subcutaneous and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model), SFX-01 produced tumour shrinkage and significantly extended survival times. SFX-01 was also found to potentiate (i.e. substantially increase) the therapeutic effect of radiotherapy in these models. Evgen now report that the in vitro these data from these experiments have been reproduced with very similar results at the University of Auckland using cells generated from freshly extracted patient GBM tissue, rather than the standard GBM cell lines established many decades previously. Further in vivo work has commenced at a contract research organisation to build upon the subcutaneous GBM tumour model experiments conducted by Dr Festuccia. Plans for a Phase II GBM clinical trial with an adaptive design are progressing with a scheduled start in the first half of 2022. In tandem work has started with regulatory advisers on preparation of an Investigational New Drug application for submission to the US Food and Drug Administration in Q4/2021. The therapeutic options for GBM are limited to surgery, radiotherapy and the one drug widely available, temozolomide. There is a clear unmet need for more treatments for use in conjunction with the current standard of care. Dr Huw Jones, Evgen CEO, commented: "Building on this data set generated by Dr Festuccia is a key step in the pathway to commencement of a clinical trial, and we are delighted that the work done at Auckland University has produced such consistent positive results. We are excited by this compelling new data set in a type of cancer which has severely limited therapeutic options for the patient and thank Professor Bruce Baguley and Dr Euphemia Leung for their advice and insightful experiments. We have started the planning for the Phase II trial and are pleased to report the GBM programme is proceeding exactly to plan."
05/6/2021
08:41
moneymunch: That's his idea of balance, repetition of the same post to be disruptive because he he has no control unlike his Guild member only threads and the reason he had the old EVG thread closed down by his lab rat assistant, and while being ignored proclaims that a debate with me is pointless and will filter me .....ha ha ha ha....i wonder why he doesn't spend more time on the other thread???? Anyways to provide balance to the European Respiratory Society living guidelines, they did provide the following in reference to SNG001, this was published befor SNG's recent phase 2 results that were decidely amibiguous because both cohort groups were from fit and healthy patients only displaying mild symptoms, that saw the share price crash from c£1.35 to below £1 after RNS phase 2 data release, which obvioulsy suggested the market wasn't impressed, until the share price recovered to c£1.75, a staggering increase of c£150m on their market cap which now sits c£320m , and the reason for the recovery was on the release of encouraging in vitro studies, yep that's right, in vitro studies, and good for them, but in vitro studies not good enough for EVG according to his biased logic....ho ho ho ho....Anyways , good luck to all holders of SNG and good look to all holders of EVG.....positive efficacy data on SFX-01 for Covid/ARDS will be transformational for all concerned and no doubt add substantial value to EVG's current bargain £24m market cap....Exciting times with a raft of newsflow from the rest of the pipeline.....also expected soon.;-) .......................... Future research: A recent trial published after the systematic review was completed demonstrated a significant benefit of inhaled interferon β-1a in 101 patients conducted in the UK [103]. While small trials should be treated with caution, this suggests the possibility that inhaled delivery has a different effect to systemic delivery of interferon. Further studies to investigate the efficacy of inhaled interferon beta are justified. hTtps://erj.ersjournals.com/content/early/2021/03/07/13993003.00048-2021
Evgen Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211027 19:14:02